

February 27, 2007

Ono Pharmaceutical Co., Ltd.
Public Relations
Phone: 06 6263 5670
Fax: 06 6263 2950

Announcement of Establishment of Strategic Alliance Headquarters

Ono Pharmaceutical Co., Ltd. (Osaka, Japan) announced today that as of March 1, 2007 Discovery Research Alliance of Research Headquarters and International Business of Development Headquarters will be integrated in a constructive way into one unit as establishing Strategic Alliance Headquarters.

In order to achieve its goal of serving as an R&D-oriented, international pharmaceutical company (global speciality) specializing in defined areas of research based on unique idea of "compound oriented" that is totally different from other companies in the industry, Ono has striven to discover original and innovative new drugs conforming to global standard in the company's four priority fields: prostaglandins, enzyme inhibitors, neuroscience, and intracellular signaling, where we can fully benefit from the technologies we have accumulated in the past, and now adding genomic drug discovery on top of these four areas.


* Compound oriented: It is an idea that development and commercialization of compounds generated from inquisitive mind of scientists towards newly discovered vital phenomena and unique theories are pursued without identifying specific disease areas.

Discovery Research Alliance, newly created in April 2005, is aggressively seeking and promoting alliances with bioventure companies and research institutions within and outside Japan in order to strengthen discovery research capability by gaining access to cutting-edge technologies and discovery seeds. This newly established section has already made remarkable achievements as launching collaborative drug discovery programs relating to inhibitors of kinase, one of the intracellular enzymes that is involved in various diseases, with two U.S. bioventure companies.

Further to that, Ono has made efforts to strengthen our development pipeline by acquiring in-licensing products aggressively.

This time, International Business of Development Headquarters that has been in charge of in- and out-licensing activities and Discovery Research Alliance of Research Headquarters that has pursued search and alliances of discovery seeds will be integrated in a constructive way into one unit as establishing Strategic Alliance Headquarters in order to further strengthen discovery research capability and expansion of development pipeline by promoting strategic alliances. Strategic Alliance Headquarters is anticipated to take an important role in improving overall research and development capability while closely coordinating with Research Headquarters and Development Headquarters.

The followings are the organization chart and description of tasks and immediate goals of each section within the Strategic Alliance Headquarters.



OPUS: Ono Pharma USA, Inc.

OPUK: Ono Pharma UK Ltd

< Discovery Research Alliance >

Discovery Research Alliance is aggressively seeking and promoting collaborative research and alliances with bioventure companies and research institutions such as universities mainly in the U.S. and Europe in order to strengthen discovery research capability and development pipeline by gaining access to discovery seeds and cutting-edge technologies.

The section is aiming at 10 new discovery alliances to be acquired from bioventure companies and new research alliances to be collaborated with 20 to 30 universities within and outside Japan during the next 5 years.

< Business Development >

The focus had been on in-licensing new drug candidates of later stages of development at Business Development, but in future the section will also direct its effort into acquiring early stage development compounds (preclinical and Phase I stage) in order to further expand our development pipeline.

The section is aiming at in-licensing 10 new compounds during the next 5 years.

< Licensing and Business Research >

Licensing and Business Research section will perform information search and collection for business alliances and promote contract negotiation by obtaining cross-sectional cooperation from other headquarters on demand.